TargetMol

Deoxynyboquinone

Product Code:
 
TAR-T27148
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27148-5mg5mg£770.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Deoxynyboquinone is a potent inducer of cancer cell death with IC(50) values between 16 and 210 nM.
CAS:
96748-86-6
Formula:
C15H12N2O4
Molecular Weight:
284.271
Purity:
0.98
SMILES:
Cc1cc(=O)[nH]c2C(=O)c3c(C(=O)c12)c(C)cc(=O)n3C

References

1. Kolossov VL, Ponnuraj N, Beaudoin JN, Leslie MT, Kenis PJ, Gaskins HR. Distinct responses of compartmentalized glutathione redox potentials to pharmacologic quinones targeting NQO1. Biochem Biophys Res Commun. 2017 Jan 29;483(1):680-686. doi: 10.1016/j.bbrc.2016.12.082. PubMed PMID: 27986568; PubMed Central PMCID: PMC5253246. 2. Lundberg AP, Francis JM, Pajak M, Parkinson EI, Wycislo KL, Rosol TJ, Brown ME, London CA, Dirikolu L, Hergenrother PJ, Fan TM. Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. Invest New Drugs. 2016 Dec 14. [Epub ahead of print] PubMed PMID: 27975234. 3. Parkinson EI, Hergenrother PJ. Deoxynyboquinones as NQO1-Activated Cancer Therapeutics. Acc Chem Res. 2015 Oct 20;48(10):2715-23. doi: 10.1021/acs.accounts.5b00365. PubMed PMID: 26444384. 4. Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, Morales JC, Motea EA, Bornmann WG, Yordy JS, Boothman DA. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxid Redox Signal. 2014 Jul 10;21(2):237-50. doi: 10.1089/ars.2013.5462. PubMed PMID: 24512128; PubMed Central PMCID: PMC4060774.